JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

Search

Zai Lab Ltd ADR

Closed

SectorHealthcare

39.43 3.85

Overview

Share price change

24h

Current

Min

37.93

Max

39.54

Key metrics

By Trading Economics

Income

33M

-48M

Sales

-2.6M

106M

Profit margin

-45.487

Employees

1,869

EBITDA

19M

-56M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+49.01% upside

Dividends

By Dow Jones

Next Earnings

7 sie 2025

Market Stats

By TradingEconomics

Market Cap

816M

4.2B

Previous open

35.58

Previous close

39.43

News Sentiment

By Acuity

50%

50%

176 / 374 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Zai Lab Ltd ADR Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

5 sie 2025, 23:11 UTC

Earnings

Australia's REA Hikes Dividend as Annual Profit Rises 23% -- Update

5 sie 2025, 22:45 UTC

Earnings

Australia's REA Hikes Dividend as Annual Profit Rises 23%

5 sie 2025, 22:39 UTC

Earnings

Great-West Lifeco Logs Lower 2Q Profit

5 sie 2025, 21:32 UTC

Earnings

Coupang Posts Higher 2Q Sales Due to Customer Growth

6 sie 2025, 00:00 UTC

Acquisitions, Mergers, Takeovers

NFL to Take 10% Stake in Disney's ESPN -- WSJ

6 sie 2025, 00:00 UTC

Acquisitions, Mergers, Takeovers

The NFL Is Taking a 10% Stake in Disney's ESPN -- WSJ

6 sie 2025, 00:00 UTC

Acquisitions, Mergers, Takeovers

Disney to Take Control of NFL Network as Part of Agreement -- WSJ

6 sie 2025, 00:00 UTC

Acquisitions, Mergers, Takeovers

Disney, NFL Strike Wide-Reaching Media-Asset Deal -- WSJ

5 sie 2025, 23:48 UTC

Market Talk

Nikkei May Decline Amid U.S. Economic Uncertainty -- Market Talk

5 sie 2025, 23:40 UTC

Market Talk

Gold Edges Higher, Supported by Fed Rate-Cut Hopes -- Market Talk

5 sie 2025, 23:19 UTC

Market Talk

Lindian Deal With Iluka Demonstrates Kangankunde Project Appeal -- Market Talk

5 sie 2025, 23:03 UTC

Market Talk
Earnings

Advanced Micro Devices' Data-Center Story Seen as Promising -- Market Talk

5 sie 2025, 22:22 UTC

Earnings

REA: Expectation of More Interest-Rate Cuts Likely to Support Buyer Demand>REA.AU

5 sie 2025, 22:21 UTC

Earnings

REA Expects FY26 Listing Volumes Broadly Flat on FY25>REA.AU

5 sie 2025, 22:20 UTC

Earnings

REA Expects September-Quarter Listings to Be Down on Year>REA.AU

5 sie 2025, 22:18 UTC

Earnings

REA July 2025 New Residential Listings Down 8% on Year>REA.AU

5 sie 2025, 22:17 UTC

Earnings

REA FY25 Australian Residential Listings Up 1% on Year>REA.AU

5 sie 2025, 22:17 UTC

Earnings

REA FY25 India Revenue A$129M Vs. A$103M>REA.AU

5 sie 2025, 22:16 UTC

Earnings

REA FY25 Core Australia Revenue A$1.54B Vs. A$1.35B>REA.AU

5 sie 2025, 22:16 UTC

Earnings

REA FY25 Core Operations Net Profit A$564.4M Vs. A$460.5M>REA.AU

5 sie 2025, 22:15 UTC

Earnings

REA Group FY25 Ebitda A$969.2M Vs. A$824.8M>REA.AU

5 sie 2025, 22:13 UTC

Earnings

REA Group Raises Dividend to A$1.38 Vs. A$1.02 >REA.AU

5 sie 2025, 22:13 UTC

Earnings

REA Group FY25 Rev A$1.67B Vs. A$1.45B >REA.AU

5 sie 2025, 22:12 UTC

Earnings

REA FY25 Core Operations Net Profit A$564.4M Vs, A$460.5M>REA.AU

5 sie 2025, 22:12 UTC

Earnings

REA Group FY25 Net A$677.9M Vs. Net A$302.8M >REA.AU

5 sie 2025, 21:58 UTC

Earnings

Novo Nordisk's Earnings Come After a Dramatic Guidance Cut. What to Look for Now. -- Barrons.com

5 sie 2025, 21:30 UTC

Earnings

AMD Gives a Strong Outlook. Why the Stock Is Falling. -- Barrons.com

5 sie 2025, 21:26 UTC

Earnings

AMD CEO Expects Embedded Segment to Return to Sequential Growth in Back Half of 2025

5 sie 2025, 21:23 UTC

Earnings

AMD CEO Sees Strong Customer Interest in MI400 Series for Large-Scale Deployments

5 sie 2025, 21:17 UTC

Earnings

AMD Expects Steep Production Ramp for MI350 Series in Back Half of Year, CEO Says

Peer Comparison

Price change

Zai Lab Ltd ADR Forecast

Price Target

By TipRanks

49.01% upside

12 Months Forecast

Average 56.7 USD  49.01%

High 75 USD

Low 38.2 USD

Based on 7 Wall Street analysts offering 12 month price targets forZai Lab Ltd ADR - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

7 ratings

6

Buy

1

Hold

0

Sell

Technical Score

By Trading Central

28.13 / 31.12Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Bearish Evidence

Long Term

Bullish Evidence

Sentiment

By Acuity

176 / 374 Ranking in Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.